{"id":"W4307492599","doi":"10.1158/1078-0432.ccr-22-2145","title":"Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma","year":2022,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Sunitinib; Tolerability; Internal medicine; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Oncology; Randomized controlled trial; Progressive disease; Soft tissue sarcoma; Phases of clinical research; Tyrosine-kinase inhibitor; Surgery; Clinical trial; Gastroenterology; Adverse effect; Cancer; Chemotherapy; Soft tissue","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002675103,0.001815779,0.002889566,0.0003687395,0.0004857717,0.001093866,0.0009411756,0.001467035,0.007038953],"category_scores_gemma":[0.001918502,0.0008003543,0.00134146,0.0002939456,0.00124726,0.000805788,0.0004231147,0.003368055,0.001079321],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001024976,"about_ca_system_score_gemma":0.002171588,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007920593,"about_ca_topic_score_gemma":0.002242837,"domain_scores_codex":[0.9992261,0.0004674097,0.00004512661,0.0001072403,0.00005621809,0.00009787186],"domain_scores_gemma":[0.9984388,0.0004073017,0.0003283178,0.0001184563,0.0000992988,0.0006079193],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9705545,0.009835615,0.0008703005,0.0003420305,0.000575158,0.00007113523,0.00004609308,0.0006304682,0.004621858,0.0001183701,0.001345775,0.01098875],"study_design_scores_gemma":[0.9472658,0.05061043,0.0006907029,0.000009850469,0.0001251359,0.00003559014,0.000009362077,0.0003717601,0.0003388352,0.00008488368,0.0004507438,0.000006935616],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9828318,0.002683128,0.0009617289,0.001347409,0.0007263437,0.00782152,0.001293455,0.0001764058,0.002158251],"genre_scores_gemma":[0.9808176,0.001506678,0.002011668,0.001584468,0.0004653411,0.008014105,0.001874333,0.00002993664,0.003695755],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007038953,"threshold_uncertainty_score":0.02354765,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4108722467131333,"score_gpt":0.5635958806909772,"score_spread":0.1527236339778439,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}